“Should Anti-CGRP Monoclonal Antibodies Always Be the Drug of First Choice for Migraine Prophylaxis in Brazil? - a Pharmacoeconomic Study”. Headache Medicine 15, no. 3 (September 30, 2024): 170–174. Accessed January 22, 2026. https://headachemedicine.com.br/hm/article/view/1308.